Partnership will advance work in precision medicine

Top state officials joined Yale science and medicine leaders for a symbolic ribbon-cutting on May 1 to celebrate expansion of the Yale Center for Genome Analysis on West Campus and its role in a new precision health initiative launched in conjunction with Yale New Haven Health System.

Yale is an established leader in the development of genome sequencing and its clinical applications in precision medicine, including newborn diseases, prenatal diagnosis and personalized treatments in Smilow Cancer Center. The university is launching, in collaboration with the Yale New Haven Health System, an initiative to study the genomic makeup of a large cohort of patients and to track their health outcomes over time, correlating these with environmental exposures. This effort, which follows the lead of the National Institutes of Health’s Precision Medicine Initiative, promises to be a major step forward in realizing the clinical potential of personalized medicine.